Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP, 1% (Twice-A-Day) in 30 g and 60 g tubes a generic version of reference listed drug CLEOCIN T® (Clindamycin Phosphate) 1% Topical Gel.. For more updates, please feel free to email us info@solaris-pharma.com
top of page
Search
Recent Posts
See AllSolaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP
bottom of page